Phase I study of MDR modulation with PSC 833 (NSC 648265) [valspodar] with a pilot study of cytogenetic risk-adapted consolidation followed by a phase II pilot study of immunotherapy with rIL-2 (NSC 373364) [interleukin-2] in previously untreated patients with AML [acute myelogenous leukemia] less than 60 years

Trial Profile

Phase I study of MDR modulation with PSC 833 (NSC 648265) [valspodar] with a pilot study of cytogenetic risk-adapted consolidation followed by a phase II pilot study of immunotherapy with rIL-2 (NSC 373364) [interleukin-2] in previously untreated patients with AML [acute myelogenous leukemia] less than 60 years

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Valspodar (Primary) ; Busulfan; Cytarabine; Daunorubicin; Etoposide; Interleukin-2
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Nov 2008 Actual end date (1 Aug 2008) added as reported by ClinicalTrials.gov.
    • 02 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top